The primary objective of this study was to evaluate Sel-Cap’s capacity for detecting EGFR mutations (Ex19del, L858R, and T790M) in plasma-derived cfDNA, by comparing it to other commonly used genotyping platforms such as peptide nucleic acid clamping (PNAclamp; currently, the most popular platform in Korea) in tumor, as well as conventional NGS (which is a non-commercialized mutation panel based on the commonly used NGS technique) and an NGS-based cancer panel in plasma. This evidence concerns the gene EGFR and cancer.